microdose glp-1 menopause THE PCCA BLOG GLP-1 Microdosing, Brain Health &

WeightWatchers Clinic and Calibrate complete the provider set

As body weight drops, health risks related to obesity often fall too

Dehydration raises nausea risk and can cause other issues, so make fluids a priority

"For consumers, the bottom line is simple: If a product claims to work 'just like a GLP-1 drug,' promises dramatic weight loss, or minimizes risk with slogans like 'all the benefits without the discomfort,' that should be a red flag," Ventura says

Research peptide vendors sell retatrutide labeled 'for research use only.' These products are not manufactured to pharmaceutical standards and are not tested or regulated by the FDA

Boehringer Ingelheim Recent Developments In April 2026 , Eli Lilly's Foundayo (orforglipron) received FDA approval for adults with obesity or overweight-related health issues